Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.44 |
| ▸ | ITGAV | P06756 | 12/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.44 |
| ▸ | PPARA | Q07869 | 7/20 | 0.33 |
| ▸ | PPARD | Q03181 | 5/20 | 0.33 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.33 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538929 | 1.00 | ITGB3 (0.44) | ITGB3ITGAVITGA2BPPARAPPARD | |
| Hydrochloric Acid SCHEMBL538366 | 0.99 | ITGB3 (0.44) | ITGB3ITGAVITGA2BPPARAPPARD | |
| Hydrochloric Acid SCHEMBL537991 | 0.99 | ITGB3 (0.44) | ITGB3ITGAVITGA2BPPARAPPARD | |
| SCHEMBL538683 | 0.95 | ITGB3 (0.46) | ITGB3ITGAVITGA2BPPARAPPARD | |
| Hydrochloric Acid SCHEMBL538176 | 0.94 | ITGB3 (0.45) | ITGB3ITGAVITGA2BPPARAPPARD | |
| SCHEMBL538585 | 0.93 | ITGB3 (0.47) | ITGB3ITGAVITGA2BPPARAITGB6 | |
| SCHEMBL2119815 | 0.93 | ITGB3 (0.47) | ITGB3ITGAVITGA2BPPARAITGB6 | |
| SCHEMBL2856751 | 0.93 | ITGB3 (0.43) | ITGB3ITGAVITGA2BPPARAITGB6 | |
| SCHEMBL2857672 | 0.93 | ITGB3 (0.43) | ITGB3ITGAVITGA2BPPARAITGB6 | |
| Hydrochloric Acid SCHEMBL538412 | 0.92 | ITGB3 (0.47) | ITGB3ITGAVITGA2BPPARAITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415474-B1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF OPHTHALMIC DISEASES | UBE INDUSTRIES (JP) | 2013-08-28 | — | — | EP | claimed |
| EP-2221308-B1 | BENZAZEPINONE COMPOUND | UBE INDUSTRIES (JP) | 2013-07-10 | — | — | EP | claimed |
| US-8377922-B2 | Benzazepinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-02-19 | — | — | US | claimed |
| US-20120095215-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF EYE DISEASES | UBE INDUSTRIES, LTD. (JP) | 2012-04-19 | — | — | US | claimed |
| EP-2415474-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF OPHTHALMIC DISEASES | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | claimed |
| US-20100249396-A1 | BENZAZEPINONE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2010-09-30 | — | — | US | claimed |
| EP-2221308-A1 | BENZAZEPINONE COMPOUND | Ube Industries, Ltd. (JP) | 2010-08-25 | — | — | EP | claimed |
| EP-2415474-B1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF OPHTHALMIC DISEASES | UBE INDUSTRIES (JP) | 2013-08-28 | — | — | EP | disclosed |
| EP-2221308-B1 | BENZAZEPINONE COMPOUND | UBE INDUSTRIES (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8377922-B2 | Benzazepinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20120095215-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF EYE DISEASES | UBE INDUSTRIES, LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2415474-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF OPHTHALMIC DISEASES | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100249396-A1 | BENZAZEPINONE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2221308-A1 | BENZAZEPINONE COMPOUND | Ube Industries, Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095215-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF EYE DISEASES | VEGFA, UACA, PGF | ITGB3 1280/4885ITGAV 2836/4885ITGA2B 2740/4885 |
| US-20100249396-A1 | BENZAZEPINONE COMPOUND | KCNJ11, KCNJ1, KCNJ2 | ITGB3 3002/4885ITGAV 3792/4885ITGA2B 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.